Funding for this research was provided by:
Institute of Infection and Immunity (144831)
Received: 17 June 2019
Accepted: 8 April 2020
First Online: 17 April 2020
Ethics approval and consent to participate
: The study was approved by the Health Sciences and Science Research Ethics Board at the University of Ottawa (certificate #H08–16-27), the Carleton University Research Ethics Board-A (CUREB-A, certificate #106300), the Social and Behavioral Institutional Review Board at Florida International University (certificate #105160), and the Research Ethics Committee at the University of Port Harcourt (certificate #UPH/CEREMAD/REC/04). Additionally, permission was obtained from each of the community partner sites where participants were recruited. Participants were informed of the potential risks associated with completing the questionnaire and that they would have limited direct benefit from their participation. They were informed that they could withdraw from the study at any time without any adverse effects. Participants were informed that completion of the questionnaire signified their informed consent to participate in the study.
: Not applicable.
: The authors declare that they have no competing interests.